Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Nina Magnolo(University Hospital Münster), Manmath Patekar(Novartis (Switzerland)), John Browning(The University of Texas at San Antonio), Vivian Laquer(Johns Hopkins University), Adam Reich(Rzeszów University of Technology), Pascal Forrer(Novartis (Switzerland)), Jacek C. Szepietowski(Wroclaw Medical University), Weibin Bao, Külli Kingo(Tartu University Hospital), P. Papanastasiou(Novartis (Switzerland)), Deborah Keefe(Novartis (United States))
Cited by 19
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748